$IRMD

Scharen-Guivel Hilda Frederique sold $117K of IRMD

Scharen-Guivel Hilda Frederique sold 1,234 shares of IRADIMED CORP (IRMD) at $95.00 ($0.12M total) on 2026-06-04.

Original reporting
SEC EDGAR · Scharen-Guivel Hilda Frederique
Published Jun 4, 2026, 8:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRMD
Neutral
medium confidence
Mentioned
$IRMD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRMDNeutralLow
01

Why it matters

This provides incremental sentiment information but lacks fundamental drivers (earnings, guidance, deals, litigation, or regulatory actions).

02

Market read

Traders may monitor whether additional insider sales/buys follow, but the disclosure alone is unlikely to materially reprice the stock.

03

What to watch

Director sales can be routine or tax-related; the article provides no reason for the sale or whether other insiders increased/decreased positions around the same time.

Relevance 6/10Novelty 6/10Timing: Filed same day (2026-06-04) as the sale disclosure

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for IRMD, reporting a director’s open-market sale.

Company-level read

Ticker impact

$IRMDNeutralMedium confidence
Context

SEC Form 4 shows IRMD director Hilda Frederique Scharen-Guivel sold 1,234 shares at $95 on 2026-06-04.

Expected impact

Likely limited immediate price impact; watch for follow-on insider activity or changes in trading plans.

Evidence & confidence

The filing is a single director sale with no stated 10b5-1 plan and no accompanying fundamental catalyst in the article.

Market effects

No sector-wide implications; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Without a 10b5-1 plan, the sale could reflect liquidity needs rather than bearish expectations; one transaction is not a trend.

Key entities

  • IRMD

    IradiMed Corp; subject of the Form 4 insider sale disclosure.

  • Scharen-Guivel Hilda Frederique

    Director who sold 1,234 shares on 2026-06-04.

Related articles

$IRMDMedAI 9/10

IRadimed (IRMD) Q2 2026 Earnings Call Transcript

IRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.

$IRMDMedAI 9/10

Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report

Iradimed Corp (IRMD) reported Q1 2026 results on May 1. The company said revenue rose 13% year over year to $22 million and net income increased 24% to $5.8 million, or $0.45 per share. Iradimed also launched its next-generation 3870 MRI-compatible IV infusion pump in Q1, with shipments expected to begin in Q2. For Q2, it forecast revenue of $20–$21 million and GAAP EPS of $0.40–$0.44; full-year 2026 revenue of $91–$96 million and GAAP EPS of $1.90–$2.05.